

## AMENDMENTS TO THE CLAIMS

1-6. (Canceled)

7. (Currently amended) A ~~vaccine~~ composition for eliciting or ~~enhancing~~ increasing the titer of antibodies specific for a cell surface receptor antigen, comprising:

a) a first recombinant expression construct containing at least one promoter operably linked to a nucleic acid sequence encoding a cell surface receptor antigen comprising a transmembrane domain and a cell surface receptor domain that binds to at least one of a cytokine, a chemokine or a growth factor; [[and]]

b) a second recombinant expression construct containing at least one promoter operably linked to a nucleic acid sequence encoding a first immune response altering molecule; and

c) a nucleic acid sequence encoding a second immune response altering molecule [[,]] ; wherein said first immune response molecule is 4-1BB-ligand and said second immune response altering molecules are different from each other and are selected from the group consisting of an accessory cell agent and a T cell agent molecule is selected from the group consisting of CD80/B7.1 and CD86/B7.2.

8. (Canceled)

9. (New) The composition of Claim 7, wherein the second recombinant expression construct comprises the nucleic acid sequence encoding the second immune response altering molecule.

10. (New) The composition of Claim 7, further comprising a third recombinant expression construct comprising the nucleic acid sequence encoding the second immune response altering molecule.

11. (New) The composition of Claim 7, wherein the cell surface receptor domain binds to at least one of a cytokine, or a chemokine.

12. (New) The composition of Claim 7, wherein the cell surface receptor domain binds to a growth factor.

13. (New) The composition of Claim 12, wherein the cell surface receptor antigen is selected from the group consisting of HER1, HER2, HER3, HER4, epidermal growth factor receptor, vascular endothelial cell growth factor receptor, insulin-like growth factor-I receptor, insulin-like growth factor-II receptor, transferrin receptor, estrogen receptor, progesterone receptor, follicle stimulating hormone receptor, and retinoic acid receptor.

14. (New) The composition of Claim 7, wherein the second immune response altering molecule is CD80/B7.1

15. (New) The composition of Claim 7, wherein the second immune response altering molecule is CD86/B7.2

16. (New) The composition of Claim 9, wherein the second recombinant expression construct further comprises an internal ribosome binding site (IRES) operably inserted between the 4-1BB-ligand and the second immune response molecule.

17. (New) The composition of Claim 7, wherein the at least one promoter in the second recombinant expression construct is the cytomegalovirus (CMV) promoter.

18. (New) The composition of Claim 7, further comprising a pharmaceutically acceptable carrier for parenteral administration selected from the group consisting of water, saline, alcohol, a fat, a wax or a buffer.

19. (New) The composition of Claim 18, wherein the recombinant constructs comprise from 0.01% to 1% of the total weight of the composition.

20. (New) The composition of Claim 7, wherein the composition further comprises at least one cytokine, or nucleic acid encoding at least one cytokine selected from the group consisting of interleukin 4 (IL-4), interleukin-12 (IL-12), interleukin-17 (IL-17), and interferon-gamma (IFN-gamma).